POZEN Receives Patent on PA Products for Treatment of Cardiovascular Disease and Osteoarthritis
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that the United States Patent and Trademark Office has issued to POZEN U.S. Patent 8,206,741 titled ‘Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs'. This patent includes claims to pharmaceutical compositions that contain aspirin and a proton pump inhibitor (PPI). POZEN's PA (PPI/aspirin) combination drug candidates are covered under this patent. The ‘741 patent is the second U.S. patent issued to POZEN for the coordinated delivery of NSAIDs, but the first in which the claims are focused on aspirin-based products.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.